Abstract
Background: To evaluate if peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have a potential protective effect on the peritoneum changes induced by bioincompatible peritoneal dialysis (PD) solution in vivo. Methods: Male Wistar rats were dialyzed three times daily for 28 days with 1.36% Dianeal® (two groups: with (D+R) or without (D) rosiglitazone) or 1.36% Physioneal® (two groups: with (P+R) or without (P) rosiglitazone). Peritoneal transport of fluid and small solutes was assessed. Nine rats that did not receive dialysis served as controls. Results: Significant morphological changes were found in the D group compared with controls. Additional use of rosiglitazone in the D+R group resulted in less morphological changes and expression of collagen I as well as an increased drainage volume. The expression of VEGF was inhibited by rosiglitazone while no apparent effect was found regarding TGF/Smad pathway. Conclusions: The addition of rosiglitazone to standard dialysis fluids can maintain the peritoneal morphology and increase ultrafiltration in a PD rat model.
Original language | English (US) |
---|---|
Pages (from-to) | 575-582 |
Number of pages | 8 |
Journal | Blood Purification |
Volume | 24 |
Issue number | 5-6 |
DOIs | |
State | Published - Dec 2006 |
Externally published | Yes |
Keywords
- Biocompatible solution
- Fibrosis
- Peritoneal dialysis
- Peroxisome proliferator-activated receptor-γ agonist
ASJC Scopus subject areas
- Hematology
- Nephrology